Teva Pharmaceutical Industries Limited (TLV:TEVA)
6,640.00
+200.00 (3.11%)
Oct 5, 2025, 3:49 PM IDT
TLV:TEVA Revenue
Teva Pharmaceutical Industries had revenue of $4.18B USD in the quarter ending June 30, 2025, with 0.29% growth. This brings the company's revenue in the last twelve months to $16.63B, up 2.07% year-over-year. In the year 2024, Teva Pharmaceutical Industries had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
$16.63B
Revenue Growth
+2.07%
P/S Ratio
1.36
Revenue / Employee
$465.95K
Employees
35,686
Market Cap
75.93B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Danel (Adir Yeoshua) | 2.84B |
Kamada | 571.15M |
Bait Bakfar | 106.25M |
BrainsWay | 155.27M |
SofWave Medical | 234.12M |
Ilex Medical | 927.57M |
Novolog (Pharm-Up 1966) | 2.04B |
InterCure | 238.85M |
Teva Pharmaceutical Industries News
- 2 days ago - FDA Initiative May Impact Teva's (TEVA) Generic Drug Endeavors - GuruFocus
- 2 days ago - JP Morgan Maintains Overweight Rating on TEVA, Price Target Raised to $26 | TEVA Stock News - GuruFocus
- 5 days ago - Unpacking the Latest Options Trading Trends in Teva Pharmaceutical Indus - Benzinga
- 5 days ago - Notable ETF Inflow Detected - IXUS, PDD, NU, TEVA - Nasdaq
- 10 days ago - Teva Releases Q3 2025 Aide Memoire - GlobeNewsWire
- 10 days ago - Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025 - GlobeNewsWire
- 10 days ago - Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors - Seeking Alpha
- 10 days ago - November 7th Options Now Available For Teva Pharmaceutical Industries (TEVA) - Nasdaq